KRAS and cancer: Despite the limited number of clinical studies investigating drugs targeting inflammation and immunomodulatory effects specifically in KRAS-mutant cancers, the forthcoming results from the trials in cancers often driven by KRAS mutations will be provide crucial knowledge for future studies.